NVCA president Mark Heesen says the sudden drop in US venture fundraising in Q3 may not be such a bad thing for VCs. Dave Keating reports.
The US property investment management firm is stepping up its European activities with two new fund of fund launches as the product gains in popularity.
The Oslo-based private equity firm has held a final close on its second fund with just over €500m in commitments, more than twice the amount raised for its vintage-2005 debut fund.
UK turnaround specialist Kelso Place has raised its third fund from just four investors closing on £100 million.
3i, a London-listed private equity firm, has invested in SVG Capital’s second fund dedicated to private equity-style investments in public companies.
Capital Today, a Shanghai-based growth capital provider, has closed its first private equity fund $80 million above target.
GTCR will invest its ninth and largest fund using the firm’s manager-focused strategy.
Global pharmaceuticals group Pfizer paid a reported $400m to acquire PowderMed, a UK DNA-vaccines company backed by Advent Venture Partners, Abingworth Management, Oxford Bioscience Partners and SV Life Sciences.
A €1bn fund dedicated to global secondaries brings Swiss asset manager Partners Group’s total fundraising to €2.6bn in the last five months.
CLSA Capital Partners, the alternative asset management arm of CLSA Asia Pacific Markets, a Hong Kong investment bank and broker, has made a partial exit from a listed Indian power distribution equipment maker.